Red blood cells (RBCs) from a rhesus D (RhD)-positive fetus that reach the bloodstream of an RhD-negative pregnant woman during birth can induce a pathogenic antibody (Ab) response against the RhD-positive RBCs, leading to fetal hemolytic disease in subsequent pregnancies. To prevent a pathogenic immune reaction, the RhD-negative mother receives serum immunoglobulin G (IgG) containing polyclonal RhD-specific IgG Abs that is purified from healthy RhD-negative men immunized with RhD-positive RBCs. However, the protective mechanism of these polyclonal RhD-specific IgG Abs is unclear. It has become increasingly clear that the effector function of IgG Abs is regulated by the glycan pattern linked to the Fc region of IgG Abs. Non-fucosylated (afucosylated) IgG Abs have a higher affinity for activating Fc gamma receptors, and thus induce a stronger Ab-dependent cellular cytotoxicity (ADCC) reaction than do fucosylated IgG Abs. Agalactosylated and asialylated, autoantigen-specific serum IgG Abs correlate with pro-inflammatory immune responses and disease activity in patients with rheumatoid arthritis. In contrast, galactosylated and sialylated IgG Abs are immunosuppressive and inhibit in form of immune complexes (ICs) dendritic cell (DC) maturation and pro-inflammatory T and B cell immune responses in an antigen-specific manner. However, the galactosylation and sialylation levels of the protective polyclonal RhD-specific IgG Abs are unknown. Here, we purified RhD-specific IgG Abs from the approved commercial product Rhophylac® (CSL Behring) and found that these RhD-specific IgG Abs were even more galactosylated and sialylated than the total Rhophylac® IgG Abs. This result suggests that these galactosylated and sialylated polyclonal RhD-specific IgG Abs are immunosuppressive and induce tolerance against RhD, which would be in strong contrast to a low fucosylated, low galactosylated and low sialylated monoclonal RhD-specific IgG Ab developed to prevent fetal hemolytic disease that has recently passed a clinical phase II study.
However, the protective mechanism of passive anti-RhD treatment remains unclear. It is hypothesized that the clearance of RhD-positive RBCs is mediated through an Fcγ receptor (Fcγ R) IIIA-mediated Ab-dependent cellular cytotoxicity (ADCC) reaction and that rapid clearance prevents immunization [1] [2] [3] [4] . To prevent immunization, it has also been suggested that polyclonal anti-RhD IgG Abs have to inhibit the activation of RhD-specific B cells through the co-ligation of the B cell receptor and an inhibitory receptor, such as the IgG inhibitory receptor FcγRIIB 2,3 . Furthermore, tolerance induction via antigen-presenting cells (APCs) has been posited to inhibit pro-inflammatory, RhD-specific T cell responses 2, 5, 6 . However, it is questionable whether FcγRIIIA crosslinking on APCs inhibits pro-inflammatory RhD-specific T cell responses but rather enforces pro-inflammatory T cell responses 7 . It is more likely that polyclonal anti-RhD IgG Abs target an inhibitory receptor (complex) on APCs to induce regulatory T cells and tolerance for inhibiting pro-inflammatory T cell and therewith also T celldepemdent B cell responses.
Attempts to substitute this polyclonal anti-RhD IgG prophylaxis with RhD-specific monoclonal IgG Abs have failed because the monoclonal RhD-specific IgG Abs were relatively unstable due to intramolecular rearrangements or did not clear RhD-positive RBCs as rapidly as the available polyclonal anti-RhD IgG Abs in in vitro assays or clinical trials and/or did not sufficiently inhibit allo-immunization in clinical trials 1, 4, 8 .
It has become increasingly clear that the effector function of IgG Abs is highly regulated by the Abs' Fc N-linked glycosylation pattern ( Figure 1A ). Non-fucosylated (afucosylated) IgG Abs have a higher affinity for activating FcγRs, such as FcγRIIIA, and thus induce a stronger ADCC reaction than do fucosylated IgG Abs 9, 10 . This finding is currently translated, for example, into tumor-specific Ab therapy.
Agalactosylated and asialylated (G0), autoantigen-specific serum IgG Abs correlate with pro-inflammatory immune responses and disease activity in patients with rheumatoid arthritis (RA) [11] [12] [13] [14] . In contrast, pregnancy-induced and anti-tumor necrosis factor (TNF) therapy-induced remission in RA patients is associated with an increase in galactosylated and sialylated IgG Abs 15, 16 . In this context, an anti-inflammatory role has been suggested for sialylated IgG Abs. Accordingly, the sialylated IgG subfraction of intravenous IgG (IVIG), which is purified from pooled human plasma from healthy donors and used to systemically treat autoimmunity in high doses (2 g/kg), exhibits anti-inflammatory activity [17] [18] [19] [20] However, based on the findings described above regarding the effector functions of differentially glycosylated IgG Abs, it is questionable whether an anti-tumor IgG1 Ab and an anti-RhD IgG1 Ab should have the same Fc glycosylation. Whether low-galactosylated, low-sialylated RhD-specific IgG Abs can inhibit the induction of pathogenic immune reactions against RhD-positive fetal RBCs or rather enhance allo-immunization is also questionable. To identify the Fc galactosylation and sialylation of RhD-specific IgG Abs in a commercially available polyclonal anti-RhD IgG product, we purified RhD-specific IgG Abs from the approved product Rhophylac® (CSL Behring, King of Prussia, PA, USA) and analyzed the Abs' Fc glycosylation.
Methods

Purification of RhD-specific IgG Abs from Rhophylac®
Total IgG from the commercial polyclonal anti-RhD IgG product Rhophylac® was purified using protein-G-sepharose (GE Healthcare, Fairfield, CT, USA). RhD-specific IgG Abs from the purified total IgG Abs of Rhophylac® were enriched using RhD-positive human erythrocytes. For this purpose, anonymous RhD-positive erythrocyte concentrates were obtained from the blood bank of the Charité -University Hospital Berlin. The erythrocyte concentrate was washed with 1 mM EDTA in PBS. Next, 20 ml of erythrocyte concentrate was diluted 1:1 with purified total IgG from Rhophylac® in PBS, which contained approximately 600 µg of RhD-specific IgG Abs as indicated by the company, and was incubated for 2h at 4°C. The erythrocytes were then washed five times with PBS. Subsequently, RhD-specific IgG Abs were eluted with 0.15 M glycine pH 3.0; neutralized with 1 M Tris/HCl pH 9.0 and dialyzed against PBS. Two independent RhD-specific IgG purifications (A and B) were done. Enrichment of the RhD-specific IgG Abs was verified by fluorescence-activated cell sorting (FACS) analysis. IgG Fc glycosylation was characterized through MALDI-TOF mass spectrometry (MS).
FACS analysis
Enrichment of the purified polyclonal RhD-specific IgG Abs was verified by FACS analysis (FACS Calibur with CellQuest Pro software, version 6.0 (BD Biosciences, Franklin Lakes, NJ, USA)). RhD-positive human RBCs were stained with 260 µg/ml of total IgG from Rhophylac® (blue), 2 µg/ml purified RhD-specific IgGs (black) or 2 µg/ml of total IgG from Rhophylac® (red) and an anti-human IgG APC-coupled secondary Ab (#550931; BD Biosciences) in cold PBS containing 0.5% bovine serum albumin (Sigma-Aldrich; St. Louis, MO, USA). The stained cells were gated on the main erythrocyte population in a FSC/SSC blot to exclude fragments and aggregates and analyzed in an anti-human IgG (APC) histogram. The data were analyzed with FlowJo 7.2.5 from Tree Star, Inc. Ashland, Oregon, USA. An overlay of different histograms, containing the analysis of the RhD-specific IgG Abs from purification A, is shown in Supplementary fi gure 1. The FCS files can be found in the data files below. 
Glycan analysis through MALDI-TOF MS
The purified total and RhD-specific IgG samples were hydrolyzed with recombinantly expressed endoglycosidase S (EndoS) from Streptococcus pyogenes, an enzyme that hydrolyzes N-glycans only from the Fc portion of the IgG Abs, to prevent the analysis of glycans from pontential contaminating RBC proteins 34 . The resulting N-glycans were purified through solid-phase extraction using reversedphase C18 and graphitized carbon columns (Alltech, Deerfield, IL, USA), permethylated and further investigated by MALDI-TOF MS 21 . The spectra were recorded on an Ultraflex III mass spectrometer (Bruker Corporation, Billerica, MA, USA) equipped with a Smartbeam laser. Calibration was performed on a glucose ladder, and 2,5-dihydroxybenzoic acid (DHB) was used as the matrix. Spectra were recorded in reflector positive ionization mode and mass spectra from 3,000 laser shots were accumulated. The crude glycan analysis data of the two independent RhD-specific IgG Ab purifications A and B can be found in the data files below. These results strongly suggest that only galactosylated and sialylated, immunosuppressive monoclonal RhD-specific IgG Abs can be substituted for polyclonal anti-RhD IgG products to inhibit pathogenic allo-immunity in RhD-negative pregnant woman. Low fucosylated, low agalactosylated and low sialylated RhD-specific IgG Abs might not only enhance pro-inflammatory immune responses against RhD-positive fetal RBCs but also have the potential to attack RhD-positive fetal RBCs after transplacental passage.
MALDI-TOF MS glycan analysis of
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23 September 2013 Referee Report: In the article "Anti-rhesus D prophylaxis…" by Winkler, Berger, and Ehlers the authors present data demonstrating enrichment of galactosylation and sialylation in the anti Rh-D fraction of Rhophylac. This study is well written with adequate discussion of methods. Moreover, the report builds on exciting recent findings that the pattern of glycosylation is an important determinant factor in the effector function of IgG providing mechanistic control of FcGR interactions and tolerogenic v.s. inflammatory immunity.Their results would suggest the therapeutic value of anti-RhD therapy may lie in an active tolerogenic response rather than via clearance mechanisms, a theory which should be tested moving forward.
The title is a bit misleading as it suggests experimental evidence contained within the report demonstrates anti-RhD activity is due to glycosylation, a theorized outcome that has yet to be demonstrated. A revision to reflect this fact may be appropriate.
Otherwise, it is an exciting report pointing to a novel mechanism that may drive prophylactic anti-RhD therapy.
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